

YASMIN KING RESIGNS AS NON-EXECUTIVE DIRECTOR

Adelaide, Australia, 7th October 2022: Australian hi-tech company Micro-X Ltd (ASX:MX1) (**Micro-X** or the **Company**), a leader in cold cathode x-ray technology for health and security markets globally, announces that Ms Yasmin King has resigned from the Board as a Non-Executive Director effective from 7th October 2022

During her tenure, Ms King also served as Chair of the Audit & Risk Committee during several capital raisings, and the challenges of the global pandemic. A new Chair will be elected shortly for this committee.

Micro-X's Managing Director, Peter Rowland, commented:

"Having worked with Yasmin as a director for nearly six years, I would like to acknowledge and thank her for her strong contribution through these critical, early growth years of our company. Yasmin leaves us with the Company now in a much stronger position than when she joined with our transition from a single-product company to one now focussed on four huge product application opportunities. Yasmin also played a lead role in our shift to in-source CNT emitter and tube technology in 2018 which has become the cornerstone platform of our four-product strategy."

Micro-X's Chairman, David Knox, commented:

"On behalf of the Board and all shareholders we very much appreciate Yasmin's service and contribution to Micro-X. We wish Yasmin all the best in her future endeavours."

An Appendix 3Z for Ms King is attached with this announcement.

This ASX Announcement is authorised by the Board of Micro-X.

– ENDS –

About Micro-X

Micro-X Limited (the Company) is an ASX listed hi-tech company developing and commercialising a range of innovative products for global health and security markets, based on proprietary cold cathode, NEX emitter technology. The electronic control of emitters with this technology enables x-ray products with significant reduction in size, weight, and power requirements, enabling greater mobility and ease of use in existing x-ray markets and a range of new and unique security and defence applications. Micro-X has a fully vertically integrated design and production facility in Adelaide, Australia. A growing technical and commercial team based in Seattle is rapidly expanding Micro-X's US business.

Micro-X's product portfolio is built in four, high margin, product lines in health and security. The first commercial mobile digital radiology products are currently sold for diagnostic imaging in global healthcare, military, and veterinary applications. An X-ray Camera for security imaging of Improvised Explosive Devices is in advanced development. The US Department of Homeland Security has selected Micro-X to design a next-generation Airport Checkpoint Portal with self-service x-ray. A miniature brain CT imager for pre-hospital stroke diagnosis in ambulances, is being developed with funding from the Australian Government's Medical Research Future Fund. For more information visit: www.micro-x.com

CONTACTS

Micro-X Limited	Micro-X Investor Enquiries
Peter Rowland, Managing Director Kingsley Hall, CFO and Company Secretary Rebecca Puddy, Head of Corporate Communications Tel: +61 8 7099 3966 E: media@micro-x.com	David Allen / John Granger Hawkesbury Partners Tel: +61 2 9103 9494 E: dallen@hawkesburypartners.com jgranger@hawkesburypartners.com

Appendix 3Z

Final Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/9/2001.

Name of entity	Micro-X Limited
ABN	21 153 273 735

We (the entity) give ASX the following information under listing rule 3.19A.3 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of director	Yasmin King
Date of last notice	22 December 2021
Date that director ceased to be director	7 November 2022

Part 1 – Director's relevant interests in securities of which the director is the registered holder

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Number & class of securities <u>Indirect</u> 228,673 Ordinary Fully Paid Shares held in the name of King McArthur Family Trust and McArthur Superfund. 60,186 Performance Rights held in the name of McArthur Superfund.
--

+ See chapter 19 for defined terms.

Appendix 3Z

Final Director's Interest Notice

Part 2 – Director's relevant interests in securities of which the director is not the registered holder

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Name of holder & nature of interest Note: Provide details of the circumstances giving rise to the relevant interest	Number & class of securities
	N/A

Part 3 – Director's interests in contracts

Detail of contract	N/A
Nature of interest	N/A
Name of registered holder (if issued securities)	N/A
No. and class of securities to which interest relates	N/A

+ See chapter 19 for defined terms.